nach oben

Erschienen in:

01.02.2015 | Original Paper

SHARPIN overexpression induces tumorigenesis in human prostate cancer LNCaP, DU145 and PC-3 cells via NF-κB/ERK/Akt signaling pathway

verfasst von: Jin Li, Yiming Lai, Yi Cao, Tao Du, Lexiang Zeng, Ganping Wang, Xianju Chen, Jieqing Chen, Yongsheng Yu, Simin Zhang, Yiming Zhang, Hai Huang, Zhenghui Guo

Erschienen in: Medical Oncology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

SHARPIN emerges higher expression in prostate cancerous tissues than in benign prostate hyperplasia by means of immunohistochemistry in our previous study. In this work, we performed the gain of function assay and find that overexpression of SHARPIN in LNCaP, DU145 and PC-3 cells promoted cell proliferation, invasiveness and reduced apoptosis. Furthermore, SHARPIN overexpression displayed elevated Bcl-2 and Survivin expression and reduced levels of Bax, cleaved caspase-3. Meanwhile, entropic expression of SHARPIN increased the levels of phosphorylated p65, IkBα, ERK and Akt, were selectively increased in these cells. Collectively, our study unraveled the ability of SHARPIN overexpression to induce tumorigenesis of prostate cancer cells through the NF-kB/ERK/Akt pathway and transformation of apoptosis-associated proteins.

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41.PubMedCrossRef

Sheng M, Kim E. The Shank family of scaffold proteins. J Cell Sci. 2000;113:1851–6.PubMed

Lim S. Sharpin, a novel postsynaptic density protein that directly interacts with the shank family of proteins. Mol Cell Neurosci. 2001;17:385–97.PubMedCrossRef

Ikeda F, Deribe YL, Skånland SS, Stieglitz B, Grabbe C, Franz-Wachtel M, van Wijk SJL, Goswami P, Nagy V, Terzic J, Tokunaga F, Androulidaki A, Nakagawa T, Pasparakis M, Iwai K, Sundberg JP, Schaefer L, Rittinger K, Macek B, Dikic I. SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis. Nature. 2011;471:637–41.PubMedCentralPubMedCrossRef

Tokunaga F, Iwai K. LUBAC, a novel ubiquitin ligase for linear ubiquitination, is crucial for inflammation and immune responses. Microbes Infect. 2012;14:563–72.PubMedCrossRef

Jung J, Kim JM, Park B, Cheon Y, Lee B, Choo SH, Koh SS, Lee S. Newly identified tumor-associated role of human Sharpin. Mol Cell Biochem. 2010;340:161–7.PubMedCrossRef

Zhang Y, Huang H, Zhou H, Du T, Zeng L, Cao Y, Chen J, Lai Y, Li J, Wang G, Guo Z. Activation of nuclear factor κB pathway and downstream targets survivin and livin by SHARPIN contributes to the progression and metastasis of prostate cancer. Cancer 2014;120:3208–18.

Ali AS, Ali S, El-Rayes BF, Philip PA, Sarkar FH. Exploitation of protein kinase C: a useful target for cancer therapy. Cancer Treat Rev. 2009;35:1–8.PubMedCrossRef

DiDonato JA, Mercurio F, Karin M. NF-κB and the link between inflammation and cancer. Immunol Rev. 2012;246(1):379–400.PubMedCrossRef

10.

Jin R, Yi Y, Yull FE, Blackwell TS, Clark PE, Koyama T, Smith JA, Matusik RJ. NF-κb gene signature predicts prostate cancer progression. Cancer Res. 2014;74(10):2763–72.PubMedCrossRef

11.

Nguyen DP, Li J, Yadav SS, Tewari AK. Recent insights into NF-κB signalling pathways and the link between inflammation and prostate cancer. Bju Int. 2014;114(2):168–76.PubMedCrossRef

12.

Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279–90.PubMedCrossRef

13.

Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24(5):7455–64.PubMedCrossRef

14.

He L, Ingram A, Rybak AP, Tang D. Shank-interacting protein–like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells. J Clin Invest. 2010;120(6):2094–108.PubMedCentralPubMedCrossRef

15.

Toulany M, Minjgee M, Saki M, Holler M, Meier F, Eicheler W, Rodemann HP. ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3 K inhibition. Cancer Biol Ther. 2014;15(3):317–28.PubMedCentralPubMedCrossRef

16.

Suire S, Hawkins P, Stephens L. Activation of Phosphoinositide 3-Kinase γ by Ras. Curr Biol. 2002;12(13):1068–75.PubMedCrossRef

17.

Zimmermann S. Phosphorylation and regulation of raf by akt (Protein kinase b). Science. 1999;286(5445):1741–4.PubMedCrossRef

18.

Deschenes-Simard X, Kottakis F, Meloche S, Ferbeyre G. ERKs in Cancer: friends or Foes? Cancer Res. 2014;74(2):412–9.PubMedCrossRef

19.

Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene. 2004;23(16):2934–49.PubMedCrossRef

20.

Strasser A, Cory S, Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 2011;30(18):3667–83.PubMedCentralPubMedCrossRef

21.

Fernald K, Kurokawa M. Evading apoptosis in cancer. Trends Cell Biol. 2013;23(12):620–33.PubMedCentralPubMedCrossRef

22.

Liu C, Yang J, Fu W, Qi S, Wang C, Quan C, Yang K. Coactivation of the PI3 K/Akt and ERK signaling pathways in PCB153-induced NF-κB activation and caspase inhibition. Toxicol Appl Pharm. 2014;277(3):270–8.CrossRef

23.

Liu Y, He J, Chen X, Li J, Shen M, Yu W, Yang Y, Xiao Z. The proapoptotic effect of formononetin in human osteosarcoma cells: involvement of inactivation of ERK and akt pathways. Cell Physiol Biochem. 2014;34(3):637–45.PubMedCrossRef

24.

Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N. Apoptosis and molecular targeting therapy in cancer. BioMed Res Int. 2014;2014:150845.PubMedCentralPubMed

25.

Ye Q, Cai W, Zheng Y, Evers BM, She Q. ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene. 2013;33(14):1828–39.PubMedCentralPubMedCrossRef

26.

Tyagi N, Bhardwaj A, Singh AP, McClellan S, Carter JE, Singh S. P-21 activated kinase 4 promotes proliferation and survival of pancreatic cancer cells through AKT- and ERK-dependent activation of NF-kappaB pathway. Oncotarget. 2014;5(18):8778–89.PubMedCentralPubMed

27.

Andersen MH, Svane IM, Becker JC, Straten PT. The universal character of the tumor-associated antigen survivin. Clin Cancer Res. 2007;13(20):5991–4.PubMedCrossRef

28.

Kanwar JR, Kamalapuram SK, Kanwar RK. Survivin signaling in clinical oncology: a multifaceted dragon. Med Res Rev. 2013;33(4):765–89.PubMedCrossRef

Titel: SHARPIN overexpression induces tumorigenesis in human prostate cancer LNCaP, DU145 and PC-3 cells via NF-κB/ERK/Akt signaling pathway
verfasst von: Jin Li
Yiming Lai
Yi Cao
Tao Du
Lexiang Zeng
Ganping Wang
Xianju Chen
Jieqing Chen
Yongsheng Yu
Simin Zhang
Yiming Zhang
Hai Huang
Zhenghui Guo
Publikationsdatum: 01.02.2015
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 2/2015
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-014-0444-3

Springer Medizin

SHARPIN overexpression induces tumorigenesis in human prostate cancer LNCaP, DU145 and PC-3 cells via NF-κB/ERK/Akt signaling pathway

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

A systematic review and meta-analysis of the association between OGG1 Ser326Cys polymorphism and cancers

Rac1 expression in epithelial ovarian cancer: effect on cell EMT and clinical outcome

Exosomal Hsp70 mediates immunosuppressive activity of the myeloid-derived suppressor cells via phosphorylation of Stat3

Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients

RBMS3 is a tumor suppressor gene that acts as a favorable prognostic marker in lung squamous cell carcinoma

Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie